Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Modified Release Dosage Form" patented technology

A solid, semi-solid, solution or suspension exhibiting an altered inherent rate of release of active and/or inert ingredient(s).

Pediatric dosage forms, methods of making and using

ActiveUS12433842B2Organic active ingredientsMetabolism disorderModified Release Dosage FormVitamin D+Metabolites
Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same.
Owner:EIRGEN PHARMA LTD

Vitamin d pediatric dosage forms, methods of making and using

PendingAU2024202877B2Modified Release Dosage FormVitamin D+Metabolites
Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed. 20 24 20 28 77 01 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 8 7 7 0 1 M a y 2 0 2 4
Owner:OPKO IRELAND GLOBAL HOLDINGS LTD(GB)

Modified release trazodone dosage forms

PCT designated stageWO2025179377A1Organic active ingredientsNervous disorderModified Release Dosage FormOral medication
The present disclosure is based on a surprising finding that a pH sensitive modified release dosage form is a suitable platform for trazodone therapy. Herein is described a pH sensitive modified release dosage form for once-a-day oral administration of trazodone, or a derivative thereof, comprising from 20% to 50% by weight of the trazodone or the derivative thereof, and from 10% to 80% of a release modifying excipient, which is a hydrogel-forming excipient. The present disclosure is also based on a surprising finding that dosage forms comprising trazodone have particular particle size distribution features that are advantageous for uniform release properties, even upon subdivision. In one such embodiment, less than 35% of the particles are 355μm to 500μm, greater than 5% of the particles are 250μm to 355μm, greater 2% of the particles are 75μm to 150μm, and greater than 5% of the particles are less than 38μm.
Owner:ALTUS FORMULATION INC